Psychedeic-Chronicle-Logo

Suggestions

  • Psychedelic News
  • DMT
  • Ketamine
  • Mescaline
  • Psilocybin
  • CEO INTERVIEWS

Psychedeic-Chronicle-Logo

Tryp Therapeutics

Tryp Therapeutics is a clinical-stage biotechnology firm focused on creating psilocybin-related compounds, including TRP-8803, for the treatment of diseases with unmet medical needs through accelerated regulatory pathways.

Tryp's Psilocybin-For-Neuropsychiatric Disorders (PFN™) project is concerned with the creation of synthetic psilocybin-related molecules as a new kind of medication for the treatment of binge eating, chronic pain, and other indications.

The University of Florida has begun enrolling subjects in collaboration with Tryp Therapeutics for a Phase II study for binge eating disorder, and Tryp Therapeutics also announced an upcoming Phase IIa clinical trial at the University of Michigan to test TRP-8802 for fibromyalgia.

Tryp Therapeutics TRP-8803 is a novel psilocybin-based drug that, through a new formulation and mode of administration, may improve efficacy, safety, and patient experience.

Tryp Therapeutics Add 2 New Provisional Patents to Intellectual Property Portfolio Psychedeic-Chronicle-Logo-White
Psychedelic News

Tryp Therapeutics Add 2 New Provisional Patents to Intellectual Property Portfolio

Recently, clinical-stage psychedelic biotechnology company Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) filed for two new provisional patents strengthening the company’s intellectual

September 30, 2022
Tryp Therapeutics Announces Psilyocbin-Assisted Patent Application for Binge Eating Disorder Treatment Psychedeic-Chronicle-Logo-White
Psychedelic News

Tryp Therapeutics Announces Psilyocbin-Assisted Patent Application for Binge Eating Disorder Treatment

Clinical-stage biotechnology Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) has strengthened their intellectual property portfolio with a new provisional patent designed to treat

June 30, 2022

Recent Posts

  • Biomind Labs Secure FDA Pre-IND Meeting for Feedback on NCE Triptax
  • Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment
  • Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use
  • atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial
  • Tryp Therapeutics Add 2 New Provisional Patents to Intellectual Property Portfolio

Recent Comments

No comments to show.

Popular

Biomind Labs Secure Pre-IND Meeting, Seek FDA Feedback on New Triptax Depression Treatment

Biomind Labs Secure FDA Pre-IND Meeting for Feedback on NCE Triptax

The well-known psychedelic biotech company Biomind Labs Inc. (NEO: BMND)

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced

Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use

Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use

Numinus Wellness Inc.’s (OTCQX: NUMIF) (TSX: NUMI) research division, Numinus

Psychedeic-Chronicle-Logo

© 2022 PSYCHEDELIC CHRONICLE
ALL RIGHTS RESERVED.

  • Psychedelic News
  • DMT
  • Ketamine
  • Mescaline
  • Psilocybin
  • CEO INTERVIEWS